NewcelX Ltd. entered into definitive securities purchase agreements for a private placement offering with accredited investors on July 31, 2026. The company agreed to sell 347,134 common shares or pre-funded warrants at $4.033 per share, along with common warrants to purchase an equal number of shares at an exercise price of $4.437. The offering is expected to generate gross proceeds of approximately $1.4 million, with potential additional proceeds of $1.5 million upon full warrant exercise. Closing is anticipated on or about August 14, 2026. Proceeds will advance NCEL-101 for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals and support working capital. The company operates in the biotechnology industry, focusing on drug development.
